Information for Patients

Information for patients on the coronavirus (COVID-19)

UPDATE:  As of 01 June 2020 the National Amyloidosis Centre has reopened. We will be conducting clinics via telephone/video-link, or where appropriate, in person. We will be in touch to let you know what type of appointment you will be having.

For FEVER PATIENTS who receive treatments at the Centre, such as Canakinumab, Anakinra and Tocilizumab, they will continue to have their appointments at this time.  Please contact Michael Wood or Bella Sombrito if you have any questions.

Information for amyloidosis patients

FDA Approval

FDA Approval

Your emotional wellbeing during the pandemic
Ideas for isolation